Articles On Patrys (ASX:PAB)

Patrys (ASX:PAB) says new preclinical data from the Garvan Institute of Medical Research has shown that its’ deoxymab antibody PAT-DX1 is able to slow tumour growth and increase survival in an animal model of pancreatic cancer....

ASX 200 health stocks index rose by 0.68% this morning, compared to the broader index which rose by 0.24%. Respiratory device specialist, 4D Medical (ASX:4DX), led the pack, rising by 7%. In its quarterly update,  the company said it has ra...

It’s been a mixed two weeks for small-cap health companies, with only 38 companies gaining ground, 74 losing it and 21 flatlining. Analytica Limited (ASX:ALT) was the biggest gainer, up 25% from 8 to 20 July, followed by  Rhinomed (ASX:RNO)...

Therapeutic antibody development company Patrys (ASX:PAB) has announced new data from non-clinical studies have confirmed its full-sized IgG deoxymab antibody, PAT-DX3, is able to cross the blood-brain barrier in an animal model of...

The Patrys Limited (ASX: PAB) share price is starting the week on a strong note. This comes after the therapeutic antibody development company announced new data from non-clinical studies of its cancer-fighting antibody, PAT-DX3. Patrys is...

It’s been a mixed two weeks for small-cap health companies, with 60 companies gaining ground and 52 losing it – and 21 flatlining. Botanix Pharma Ltd (ASX:BOT) was the biggest gainer, up 38% from 23 June to 7 July, and Suda Pharmaceuticals...

Each week, Stockhead recaps ASX stocks that are “running hot” as deduced by the Relative Strength Index (RSI). The RSI is a technical gauge which measures how trading momentum is affecting the price action. A reading of 70 is seen as the le...

Ask A Fund Manager The Motley Fool chats with fund managers so that you can get an insight into how the professionals think. In part 1 of our interview, 1851 Capital portfolio manager Martin Hickson tells us the telecommunications company...

Closing Bell is Stockhead’s daily recap of the ASX’s biggest winners and losers during the trading day. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intrad...

Fertoz Ltd (ASX:FTZ) topped the pops with a red hot 14-day RSI of 93 after two massive days to finish the week. A total of 18 ASX companies posted a 14-day RSI above 70 last week, down from 25 in the week prior. Each week, Stockhead recaps...

Closing Bell is Stockhead’s daily recap of the ASX’s biggest winners and losers during the trading day. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intrad...

Summary After the launch update of Aussie BubsTM-branded formula range on Walmart.com, the BUB share price shot up by 29.3%. Today, the AWN share price surged 27.5% to AU$1.02, clocking a heavy volume of over 1.7 million shares. The m...

Recent advances in our still-shallow understanding of the human brain have led to a renewed interest in companies that focus on neuroscience. The most famous neuroscience startup, Elon Musk’s Neuralink, is probably the first company that co...

Summary The ASX 200 breached 7,400 level for the first time to hit a fresh high of 7,406.20. The index closed 6.70 points higher at 7,386.20 ahead of the US Fed meeting scheduled tonight. The widely anticipated US Fed policy statement...

Closing Bell is Stockhead’s daily recap of the ASX’s biggest winners and losers during the trading day. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intrad...

Summary Neuroprotective drug developer Argenica Therapeutics commenced trading on the ASX after a well-supported AU$7 million capital raising. The Company disclosed that the ASX listing would allow it to develop its novel neuroprotecti...

Summary The ASX 200 was trading higher by 12.70 points or 0.17% at 7315.20 by mid-session, led by tech, materials and telecom stocks. The Information Technology sector was the top performer, tracking overnight gains in the tech-heavy N...

Here’s our fortnightly wrap of all the news driving ASX health stocks. The healthcare sector has returned 2.3 per cent for the last two weeks, compared to the broader market which rose by 2.7 per cent. The biggest news globally was out of U...

It was a good day for some of ASX-listed cancer therapy stocks yesterday, with three companies releasing seperate announcements that sent their share prices higher. Cancer therapy stocks Invion (ASX:IVX), Immutep (ASX:IMM), and Imugene (ASX...

Closing Bell is Stockhead’s daily recap of the ASX’s biggest winners and losers. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intraday trade. WINNERS Scrol...

Closing Bell is Stockhead’s daily recap of the ASX’s biggest winners and losers. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intraday trade.   WINNERS Scr...

Closing Bell is Stockhead’s daily recap of the ASX’s biggest movers – the winners and losers alike. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intraday t...

Here’s our fortnightly wrap of all the news driving ASX health stocks. It’s been a mixed two weeks for small-cap health companies, with 58 companies gaining ground and 54 losing it. Another 16 were flat. Code Company Price % return...

Summary Two directors of Australia’s Crown Resorts Ltd (ASX:CWN) resigned just a day after a report deemed the casino giant unfit to hold a gambling licence for its new Sydney resort. The report by the New South Wales state’s gambling...

Summary Melbourne based biotech company Patrys Limited has selected an optimised stable cell line for the development of PAT-DX1. With the selection of the stable and high-yield cell line, the Company will establish largescale manufact...

Summary After raising A$7.3 million via a placement, the company is now sufficiently funded to accelerate its development programs. During the quarter, the company reported a net cash outflow of A$667k from the operating activities. T...

The funds raised through the placement and rights issue will position the company to effectively leverage the wide range of therapeutic opportunities provided by its unique Deoxymab platform.

Therapeutic antibody development company Patrys (ASX:PAB) has announced the Australian patent titled 'Antibody-mediated Autocatalytic, Targeted Delivery of Nanocarrier to Tumors' has been granted.

Therapeutic antibody development company Patrys (ASX: PAB) has been granted an Australian patent covering the use of its novel Deoxymab platform conjugated to nanoparticles (NP) for the targeted delivery of anti-cancer drugs. The patent is...

Australian antibody development company Patrys (ASX:PAB) says it has completed initial production and characterisation of PAT-DX3, a full-sized, humanised antibody version of its dimerised antibody fragment PAT-DX1.

A quick wrap of the ASX’s key winners and losers on Wednesday, September 16. Data is taken after the market closes at 4pm AEST. Stocks highlighted in yellow made potentially market-moving announcements during the day. WINNERS TICKE...

A quick wrap of the ASX’s key winners and losers on Tuesday, September 15. Data is taken after the market closes at 4pm AEST. Stocks highlighted in yellow made potentially market-moving announcements during the day. WINNERS TICKER N...

A quick wrap of the ASX’s key winners and losers on Wednesday, September 9. Data is taken after the market closes at 4pm AEST. Stocks highlighted in yellow have made market moving announcements during the day. Today 393 stocks rose, 998 dec...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Patrys (ASX:PAB) has announced a fully underwritten and non-renounceable rights issue to raise $4.29 million before costs.

On Stockhead today, how a ‘tired’ gold mine transformed shell company Bellevue into a $650m market darling, cobalt has stumbled this year but EV growth is expected to drive demand and prices and is this a new dawn for nickel? But first…   T...

Melbourne-based therapeutic antibody development company Patrys (ASX:PAB) has announced the inventor of the Deoxymab technology platform, Dr James Hansen of the Yale School of Medicine, has been awarded a research grant from the US...

Melbourne-based therapeutic antibody development company Patrys (ASX:PAB) has announced the appointment of US-based biotechnology executive, Dr Peter Ordentlich, to its Scientific Advisory Board.

Stockhead’s resident Health and Biotech expert Tim Boreham is putting down the microscope and picking up the microphone for another instalment of The Health Kick Podcast. In this episode Tim chats with Dr James Campbell, CEO of Patrys (ASX:...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Australian company Patrys (ASX:PAB), a therapeutic antibody development company, has announced new pre-clinical data for its lead candidate, PAT-DX1.

According to CEO and managing director Dr James Campbell, “Following ongoing discussions at several partnering events, Patrys has expanded efforts to leverage the platform technology applications of the Deoxymab technology."

It’s shaping up as another coronavirus-related bloodbath on local markets this morning. But within the listed small caps there are still some select winners — particularly health care stocks that report positive clinical updates. Patrys (AS...

A pre-clinical animal study by Australian therapeutic antibody company Patrys (ASX: PAB) has shown the development drug PAT-DX1-NP is able to cross the blood brain barrier and successfully target triple-negative breast cancer brain metastas...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Patrys (ASX:PAB), an Australian therapeutic antibody development company, has announced the upcoming presentation of scientific data regarding its lead candidate, PAT-DX1.

The health sector was the most successful sector on the ASX in 2019. Various small caps made several breakthroughs including with nerve damage and macular degeneration. While cancer remains one fish that has yet to be fried there are small...

In 2019 the culmination of decades worth of work turned several biotechs and life sciences companies into overnight successes. As investors look to defensive growth stocks to compensate for a sluggish economy and with expectations of more h...

The Small-cap stocks have the potential to deliver higher returns within a shorter span of time. As these stocks are underfollowed in the market, so any significant news or that of completion of a project may uplift the share prices. Most o...

Prescient Therapeutics Limited (ASX: PTX) is an Australian clinical stage oncology company that is into the development of personalised medicines for the treatment of multiple cancers. The company aims to develop novel drugs that work on th...